Poster
110
(#110) Treatment Patterns and Healthcare Resource Utilization of Patients Early in Schizophrenia Illness Initiating Aripiprazole Lauroxil Versus Oral Aripiprazole: A Retrospective Claims-Based Study
Psych Congress 2025
Abstract: INTRODUCTION: This study compared real-world treatment patterns and healthcare resource utilization (HCRU) among early-in-illness patients with schizophrenia initiating the long-acting injectable aripiprazole lauroxil (AL) versus oral aripiprazole (OA).
METHODS: This retrospective analysis used MarketScan US administrative claims data (1/1/2016-6/30/2022). Adults aged 18-40 years with first observed diagnosis of schizophrenia on or after January 1, 2017, no antipsychotic claims ≤12 months before diagnosis, ≥2 AL or OA claims (first claim ≤1 year of first schizophrenia diagnosis code), and continuous enrollment ≥12 months before and after their first (index) AL or OA claim were eligible. Adherence (proportion of days covered), persistence, and HCRU (proportion with ≥1 visit; visits per patient per month [PPPM]) were compared between 1:1 propensity score-matched cohorts.
RESULTS: Early-in-illness patients initiating AL (n=131) had a mean age of 27.2 years; 38.9% were female (OA: n=1222, 27.2 years, 47.1% female). In matched early-in-illness cohorts, greater adherence and longer persistence were observed for AL versus OA (both P 0.0001). Odds of ≥1 all-cause emergency department (ED) visit were significantly reduced for AL versus OA (odds ratio [95% CI], 0.59 [0.36, 0.96]). All-cause inpatient and ED visits PPPM were significantly reduced with AL versus OA (rate ratios [95% CI], 0.63 [0.45, 0.83] and 0.60 [0.43, 0.78], respectively), as were mental health-related inpatient visits PPPM (0.63 [0.45, 0.84]) and ED visits PPPM (0.50 [0.35, 0.69]).
CONCLUSIONS: Early-in-illness patients with schizophrenia initiating AL versus OA in real-world settings were more persistent and adherent to treatment and had significantly lower acute HCRU.
Short Description: This study compared real-world treatment patterns and 12-month healthcare resource utilization (HCRU) among early-in-illness patients with schizophrenia (aged 18-40 years) initiating the long-acting injectable aripiprazole lauroxil (AL) versus oral aripiprazole (OA) using US administrative claims data. In matched early-in-illness cohorts, patients with schizophrenia initiating AL versus OA in real-world treatment settings were more persistent and adherent to treatment and had significantly lower acute HCRU.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
METHODS: This retrospective analysis used MarketScan US administrative claims data (1/1/2016-6/30/2022). Adults aged 18-40 years with first observed diagnosis of schizophrenia on or after January 1, 2017, no antipsychotic claims ≤12 months before diagnosis, ≥2 AL or OA claims (first claim ≤1 year of first schizophrenia diagnosis code), and continuous enrollment ≥12 months before and after their first (index) AL or OA claim were eligible. Adherence (proportion of days covered), persistence, and HCRU (proportion with ≥1 visit; visits per patient per month [PPPM]) were compared between 1:1 propensity score-matched cohorts.
RESULTS: Early-in-illness patients initiating AL (n=131) had a mean age of 27.2 years; 38.9% were female (OA: n=1222, 27.2 years, 47.1% female). In matched early-in-illness cohorts, greater adherence and longer persistence were observed for AL versus OA (both P 0.0001). Odds of ≥1 all-cause emergency department (ED) visit were significantly reduced for AL versus OA (odds ratio [95% CI], 0.59 [0.36, 0.96]). All-cause inpatient and ED visits PPPM were significantly reduced with AL versus OA (rate ratios [95% CI], 0.63 [0.45, 0.83] and 0.60 [0.43, 0.78], respectively), as were mental health-related inpatient visits PPPM (0.63 [0.45, 0.84]) and ED visits PPPM (0.50 [0.35, 0.69]).
CONCLUSIONS: Early-in-illness patients with schizophrenia initiating AL versus OA in real-world settings were more persistent and adherent to treatment and had significantly lower acute HCRU.
Short Description: This study compared real-world treatment patterns and 12-month healthcare resource utilization (HCRU) among early-in-illness patients with schizophrenia (aged 18-40 years) initiating the long-acting injectable aripiprazole lauroxil (AL) versus oral aripiprazole (OA) using US administrative claims data. In matched early-in-illness cohorts, patients with schizophrenia initiating AL versus OA in real-world treatment settings were more persistent and adherent to treatment and had significantly lower acute HCRU.
Name of Sponsoring Organization(s): This study was sponsored by Alkermes, Inc. Medical writing and editorial support were provided by Peloton Advantage, LLC, an OPEN Health company, and funded by Alkermes, Inc.
